Aerovate Therapeutics, Inc.
AVTE
$0.06
Change (1 day)
$32.42
Year High
$1.25
Year Low
Categories
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Earnings for Aerovate Therapeutics, Inc. (AVTE)
Earnings in 2023 (TTM): $-75,465,000
According to Aerovate Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-75,465,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Aerovate Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-75,465,000 | $-75,521,000 |
| 2022 | $-51,486,000 | $-51,511,000 |
| 2021 | $-22,960,000 | $-22,963,000 |
| 2020 | $-9,611,000 | $-9,039,000 |
| 2019 | $-3,330,000 | $-3,330,000 |